Treatment with IFN-gamma increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides

J Dermatol Sci. 2005 Jun;38(3):189-95. doi: 10.1016/j.jdermsci.2005.01.005. Epub 2005 Feb 16.

Abstract

Background: Interferon-gamma (IFN-gamma) is used for the treatment of mycosis fungoides, which is a Th2 neoplasm with elevation of serum Th2 chemokines. Although therapeutic effectiveness of IFN-gamma is caused at least partly by augmented activity of cytotoxic T cells against the tumor cells, its modulation on chemokine production remains unknown.

Objective: Alterations in the serum levels of Th1 chemokines, IP-10 and MIG, and Th2 chemokines, TARC and MDC, were examined in mycosis fungoides patients treated with recombinant IFN-gamma.

Methods: Four patients with mycosis fungoides received intravenous injections of IFN-gamma for 14 or 28 days. On day 0, 7, 14, and 28, sera were obtained from the patients, and the concentrations of TARC, MDC, IP-10, and MIG were measured by ELISA, along with the percentages of peripheral blood Th1 and Th2 cells.

Results: Whereas the levels of TARC and MDC were decreased by IFN-gamma treatment, those of IP-10 and MIG were increased. In particular, the increment of MIG was remarkable. No substantial change of Th1 or Th2 cell number was observed.

Conclusion: In IFN-gamma treatment as well as other therapies, TARC may serve as a marker for the disease activity of mycosis fungoides. The dramatic elevation of MIG by IFN-gamma suggests the strong dependency of MIG production on IFN-gamma and the participation of MIG in skin-infiltration of tumoricidal cytotoxic T cells.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Chemokine CCL17
  • Chemokine CCL22
  • Chemokine CXCL10
  • Chemokine CXCL9
  • Chemokines / blood*
  • Chemokines, CC / blood
  • Chemokines, CXC / blood
  • Female
  • Humans
  • Injections, Intravenous
  • Intercellular Signaling Peptides and Proteins / blood
  • Interferon-gamma / administration & dosage
  • Interferon-gamma / therapeutic use*
  • Male
  • Middle Aged
  • Mycosis Fungoides / drug therapy*
  • Mycosis Fungoides / immunology*
  • Phenotype
  • Recombinant Proteins
  • Th1 Cells / drug effects
  • Th1 Cells / immunology
  • Th2 Cells / drug effects
  • Th2 Cells / immunology
  • Time Factors

Substances

  • CCL17 protein, human
  • CCL22 protein, human
  • CXCL10 protein, human
  • CXCL9 protein, human
  • Chemokine CCL17
  • Chemokine CCL22
  • Chemokine CXCL10
  • Chemokine CXCL9
  • Chemokines
  • Chemokines, CC
  • Chemokines, CXC
  • Intercellular Signaling Peptides and Proteins
  • Recombinant Proteins
  • Interferon-gamma